H1N1: boost to Novartis Vaccines, the industry but for how long?
30 January 2010, 4:21 am
LONDON, UK—-28th January 2010—-ExpertREACT. The recent results from Novartis AG group revealed that in 2009, H1N1 vaccine sales gave an extra $1 bn to the Vaccines and Diagnostics division. This much needed boost finally lifts the division to a respectable level of profitability but will also benefit other flu players with better underlying businesses. VacZine Analytics discusses the issues and the biggest windfall in the industry yet. READ ARTICLE.
H1N1: boost to Novartis Vaccines, the industry but for how long?
LONDON, UK—-28th January 2010—-ExpertREACT. The recent results from Novartis AG group revealed that in 2009, H1N1 vaccine sales gave an extra $1 bn to the Vaccines and Diagnostics division. This much needed boost finally lifts the division to a respectable level of profitability but will also benefit other flu players with better underlying businesses. VacZine Analytics discusses the issues and the biggest windfall in the industry yet. READ ARTICLE.